Conference call to review data from the Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127 at the 65th Annual ASH Meeting to be held on December 11 at 11 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics price target lowered to $9 from $12 at Morgan Stanley
- Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
- FDA puts partial clinical hold on Nurix’s Phase 1 NX-2127-001 study
- Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial